Skip to content

Effect of product on pimple spots

To evaluate the in-vivo efficacy and safety of a skin care formulation in terms of reduction in hyperpigmentation, skin glow and skin radiance on healthy female subjects. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072028
Enrollment
36
Registered
2024-08-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L819- Disorder of pigmentation, unspecified

Interventions

Intervention1: Vit C: Product is applied on whole face once in a day for period of 28 days Control Intervention1: Nil: NA

Sponsors

Onesto Labs Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Indian female subjects. 2. Healthy subjects 3. Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….). 4. Having hyperpigmentation (Acne PIH) dark spot

Exclusion criteria

Exclusion criteria: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months. • Having refused to give her assent by signing the consent form. • Taking part in another study liable to interfere with this study. • Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area. • Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months). • Having a progressive asthma (either under treatment or last fit in the last 2 years). • Being epileptic. • Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months). • Having cutaneous hypersensitivity • Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products or food products or to latex • Having known allergy to any of the Ingredient of the Test Product. • Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) • Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.

Design outcomes

Primary

MeasureTime frame
Reduction in hyperpigmentation (Acne PIH), improvement in skin glow & skin radianceTimepoint: Baseline, Day14, Day28

Secondary

MeasureTime frame
NilTimepoint: NA

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

poojayadav@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026